FDA Grants Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
The primary outcome was a 90-day incidence of mortality or liver transplant for individuals who received larsucosterol, compared to the placebo group.
Source: pharmacytimes.com